Risks associated with mass-produced compounded GLP-1s Although the FDA has declared that the supply shortage is resolved, some companies continue to mass produce compounded versions of GLP-1s, claiming that the drugs are personalized for patient needs by altering the method of delivery (e.g., gummy, injection, spray) or adding unnecessary and unproven ingredients like B12 and glycine
These drugs are commonly prescribed for weight management, to treat type 2 diabetes, or to reduce the risk of heart attacks and stroke in people with cardiovascular disease
These measures are straightforward to calculate and have been successfully used to develop predictive disease biomarkers previously 25
In the TRIUMPH-4 Phase 3 trial disclosed by Lilly in March last year, the share of participants experiencing nausea over 68 weeks of treatment was 38.1% in the 9mg group and 43.2% in the 12mg group
The grouping makes no claim about any combined effect
Can I take these tablets with other medications or supplements